logo
logo

Buzzkill Labs Closes Oversubscribed Series A Financing

May 17, 2023•about 2 years ago

Round Type

series a

LivermoreInformation Technology

Investors

Poseidon

Description

Buzzkill Labs ("Buzzkill"), developer of the world's first rapid saliva test for psychoactive THC, today announced the close of an oversubscribed Series A funding round co-led by Poseidon and existing investors. Buzzkill will use the proceeds from the financing to commercialize its technology, which fills employers' critical need to maintain safe workplaces while respecting the dignity of employees who legally use cannabis outside of work.

Company Information

Company

Buzzkill Labs

Location

1911 2ND STREET

Livermore, California, United States

About

Buzzkill Labs is modernizing drug testing for a world of legal cannabis. We are developing and commercializing portable, rapid, cost-effective testing of oral fluid (saliva) that distinguishes and measures THC parent compound, the psychoactive component of cannabis that causes impairment. Our technology helps to eliminate cheating and to determine current potential impairment versus past use with no interference from CBD or metabolites in 15 minutes.

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Related People